The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 480-494

  Hovland, Anders ^a,b   Jonasson, Lena ^c   Garred, Peter ^d   Yndestad, Arne ^e,f   Aukrust, Pål ^e,f   Lappegård, Knut T ^a,b   Espevik, Terje ^g   Mollnes, Tom E ^a,b,e,f,g  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c LINKÖPING UNIVERSITY   (Sweden)

^d Rigshospitalet   (Denmark)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

^g NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Atherosclerosis; Inflammation; The complement system; Toll like receptors

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BIOLOGICAL MARKER; CD11B ANTIGEN; CD18 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT RECEPTOR; DECAY ACCELERATING FACTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; AUTACOID;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; EXPERIMENTAL ATHEROSCLEROSIS; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTERVENTION STUDY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL, LDL; COMPLEMENT C3A; COMPLEMENT C5A; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; MICE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84931268779     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.05.038     Document Type: Review

References (201)

1. Heidenreich P.A., Trogdon J.G., Khavjou O.A., Butler J., Dracup K., Ezekowitz M.D., Finkelstein E.A., Hong Y., Johnston S.C., Khera A., Lloyd-Jones D.M., Nelson S.A., Nichol G., Orenstein D., Wilson P.W., Woo Y.J. Council on cardiovascular surgery and anesthesia, and interdisciplinary council on quality of care and outcomes research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011, 123:933-944.
2. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 2006, 6:508-519.
3. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat. Immunol. 2011, 12:204-212.
4. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat. Med. 2002, 8:1211-1217.
5. Skålen K., Gustafsson K., Rydberg E.K., Mattson Hulten L., Wiklund O., Innerarity T.L., Boren J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750-754.
6. Tabas I., Williams K.J., Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844.
7. Ait-Oufella H., Taleb S., Mallat Z., Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2011, 31:969-979.
8. Frostegård J., Ulfgren A.K., Nyberg P., Hedin U., Swedenborg J., Andersson U., Hansson G.K. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999, 145:33-43.
9. Kyaw T., Tipping P., Toh B.H., Bobik A. Current understanding of the role of B cell subsets and intimal and adventitial B cells in atherosclerosis. Curr. Opin. Lipidol. 2011, 22:373-379.
10. Ponnuswamy P., Van Vré E.A., Mallat Z., Tedgui A. Humoral and cellular immune responses in atherosclerosis: spotlight on B- and T-cells. Vasc. Pharmacol. 2012, 56:193-203.
11. Wigren M., Nilsson J., Kolbus D. Lymphocytes in atherosclerosis. Clin. Chim. Acta 2012, 413:1562-1568.
12. Colin S., Chinetti-Gbaguidi G., Staels B. Macrophage phenotypes in atherosclerosis. Immunol. Rev. 2014, 262:153-166.
13. Medbury H.J., Williams H., Fletcher J.P. Clinical significance of macrophage phenotypes in cardiovascular disease. Clin. Transl. Med. 2014, 3:63.
14. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
15. Boyle J.J., Johns M., Kampfer T., Nguyen A.T., Game L., Schaer D.J., Mason J.C., Haskard D.O. Activating transcription factor 1 directs Mhem atheroprotective macrophages through coordinated iron handling and foam cell protection. Circ. Res. 2012, 110:20-33.
16. Erbel C., Tyka M., Helmes C.M., Akhavanpoor M., Rupp G., Domschke G., Linden F., Wolf A., Doesch A., Lasitschka F., Katus H.A., Gleissner C.A. CXCL4-induced plaque macrophages can be specifically identified by co-expression of MMP7+S100A8+ invitro and invivo. Innate Immun. 2015, 21:255-265.
17. Ruan C.C., Ge Q., Li Y., Li X.D., Chen D.R., Ji K.D., Wu Y.J., Sheng L.J., Yan C., Zhu D.L., Gao P.J. Complement-mediated macrophage polarization in perivascular adipose tissue contributes to vascular injury in deoxycorticosterone acetate-salt mice. Arterioscler. Thromb. Vasc. Biol. 2015, 35:598-606.
18. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 2011, 17:1410-1422.
19. Gonçalves I., Gronholdt M.L., Söderberg I., Ares M.P., Nordestgaard B.G., Bentzon J.F., Fredrikson G.N., Nilsson J. Humoral immune response against defined oxidized low-density lipoprotein antigens reflects structure and disease activity of carotid plaques. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1250-1255.
20. Hartvigsen K., Chou M.Y., Hansen L.F., Shaw P.X., Tsimikas S., Binder C.J., Witztum J.L. The role of innate immunity in atherogenesis. J.Lipid Res. 2009, 50(Suppl.l):S388-S393.
21. Carroll M.C., Isenman D.E. Regulation of humoral immunity by complement. Immunity 2012, 37:199-207.
22. Kolev M., Le Friec G., Kemper C. The role of complement in CD4(+) T cell homeostasis and effector functions. Semin. Immunol. 2013, 25:12-19.
23. den Dekker W.K., Cheng C., Pasterkamp G., Duckers H.J. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 2010, 209:314-320.
24. Lundberg A.M., Yan Z.Q. Innate immune recognition receptors and damage-associated molecular patterns in plaque inflammation. Curr. Opin. Lipidol. 2011, 22:343-349.
25. Mann D.L. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ. Res. 2011, 108:1133-1145.
26. Seneviratne A.N., Sivagurunathan B., Monaco C. Toll-like receptors and macrophage activation in atherosclerosis. Clin. Chim. Acta 2012, 413:3-14.
27. Haskard D.O., Boyle J.J., Mason J.C. The role of complement in atherosclerosis. Curr. Opin. Lipidol. 2008, 19:478-482.
28. Speidl W.S., Katsaros K.M., Kastl S.P., Zorn G., Huber K., Maurer G., Wojta J., Christ G. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. Atherosclerosis 2010, 208:285-289.
29. Torzewski M., Bhakdi S. Complement and atherosclerosis-united to the point of no return?. Clin. Biochem. 2013, 46:20-25.
30. Bordet J. Les leukocytes et les proprietes actives du serum chez les vaccines. Ann. Inst. Pasteur 1895, 9:462-506.
31. Walport M.J. Complement. First of two parts. N.Engl. J. Med. 2001, 344:1058-1066.
32. Walport M.J. Complement. Second of two parts. N.Engl. J. Med. 2001, 344:1140-1144.
33. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
34. Geertinger P., Sorensen H. Complement and arteriosclerosis. Atherosclerosis 1973, 18:65-71.
35. Seifert P.S., Kazatchkine M.D. The complement system in atherosclerosis. Atherosclerosis 1988, 73:91-104.
36. Garred P., Honoré C., Ma Y.J., Munthe-Fog L., Hummelshøj T. MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. Mol. Immunol. 2009, 46:2737-2744.
37. Ma Y.J., Skjoedt M.O., Garred P. Collectin-11/MASP complex formation triggers activation of the lectin complement pathway-the fifth lectin pathway initiation complex. J.Innate Immun. 2013, 5:242-250.
38. Morgan B.P. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem. J. 1989, 264:1-14.
39. Huber-Lang M., Sarma J.V., Zetoune F.S., Rittirsch D., Neff T.A., McGuire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., Gebhard F., Younger J.G., Drouin S.M., Wetsel R.A., Ward P.A. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 2006, 12:682-687.
40. Clark A., Weymann A., Hartman E., Turmelle Y., Carroll M., Thurman J.M., Holers V.M., Hourcade D.E., Rudnick D.A. Evidence for non-traditional activation of complement factor C3 during murine liver regeneration. Mol. Immunol. 2008, 45:3125-3132.
41. Amara U., Rittirsch D., Flierl M., Bruckner U., Klos A., Gebhard F., Lambris J.D., Huber-Lang M. Interaction between the coagulation and complement system. Curr. Top. Complement II 2009, 68-76.
42. Krisinger M.J., Goebeler V., Lu Z., Meixner S.C., Myles T., Pryzdial E.L., Conway E.M. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 2012, 120:1717-1725.
43. Atkinson J.P., Goodship T.H. Complement factor H and the hemolytic uremic syndrome. J.Exp. Med. 2007, 204:1245-1248.
44. Luzzatto L., Gianfaldoni G. Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria. Int. J. Hematol. 2006, 84:104-112.
45. Cicardi M., Bork K., Caballero T., Craig T., Li H.H., Longhurst H., Reshef A., Zuraw B. HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012, 67:147-157.
46. Parker C.J. Paroxysmal nocturnal hemoglobinuria. Curr. Opin. Hematol. 2012, 19:141-148.
47. Lappegård K.T., Christiansen D., Pharo A., Thorgersen E.B., Hellerud B.C., Lindstad J., Nielsen E.W., Bergseth G., Fadnes D., Abrahamsen T.G., Høiby E.A., Schejbel L., Garred P., Lambris J.D., Harboe M., Mollnes T.E. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:15861-15866.
48. Schejbel L., Fadnes D., Permin H., Lappegård K.T., Garred P., Mollnes T.E. Primary complement C5 deficiencies - molecular characterization and clinical review of two families. Immunobiology 2013, 218:1304-1310.
49. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: therapeutic interventions. J.Immunol. 2013, 190:3839-3847.
50. Weisman H.F., Bartow T., Leppo M.K., Marsh H.C., Carson G.R., Concino M.F., Boyle M.P., Roux K.H., Weisfeldt M.L., Fearon D.T. Soluble human complement receptor type 1: invivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990, 249:146-151.
51. Testa L., Van Gaal W.J., Bhindi R., Biondi-Zoccai G.G., Abbate A., Agostoni P., Porto I., Andreotti F., Crea F., Banning A.P. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J.Thorac. Cardiovasc Surg. 2008, 136:884-893.
52. Smith P.K., Shernan S.K., Chen J.C., Carrier M., Verrier E.D., Adams P.X., Todaro T.G., Muhlbaier L.H., Levy J.H. PRIMO-CABG II Investigators. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J.Thorac. Cardiovasc Surg. 2011, 142:89-98.
53. Broz P., Monack D.M. Newly described pattern recognition receptors team up against intracellular pathogens. Nat. Rev. Immunol. 2013, 13:551-565.
54. Medzhitov R., Janeway C.A. Decoding the patterns of self and nonself by the innate immune system. Science 2002, 296:298-300.
55. Matzinger P. An innate sense of danger. Semin. Immunol. 1998, 10:399-415.
56. Chang Z.L. Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm. Res. 2010, 59:791-808.
57. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
58. Latz E., Visintin A., Lien E., Fitzgerald K.A., Monks B.G., Kurt-Jones E.A., Golenbock D.T., Espevik T. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J.Biol. Chem. 2002, 277:47834-47843.
59. Kagan J.C., Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 2006, 125:943-955.
60. Halaas O., Husebye H., Espevik T. The journey of Toll-like receptors in the cell. Adv. Exp. Med. Biol. 2007, 598:35-48.
61. Kagan J.C., Su T., Horng T., Chow A., Akira S., Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat. Immunol. 2008, 9:361-368.
62. Nilsen N.J., Vladimer G.I., Stenvik J., Orning M.P., Zeid-Kilani M.V., Bugge M., Bergstroem B., Conlon J., Husebye H., Hise A.G., Fitzgerald K.A., Espevik T., Lien E. Arole for the adaptor proteins TRAM and TRIF in toll-like receptor 2 signaling. J.Biol. Chem. 2015, 290:3209-3222.
63. Vabulas R.M., Ahmad-Nejad P., da Costa C., Miethke T., Kirschning C.J., Häcker H., Wagner H. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J.Biol. Chem. 2001, 276:31332-31339.
64. Roelofs M.F., Boelens W.C., Joosten L.A.B., Abdollahi-Roodsaz S., Geurts J., Wunderink L.U., Schreurs B.W., van den Berg W.B., Radstake T.R.D.J. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential Involvement in the pathogenesis of rheumatoid arthritis. J.Immunol. 2006, 176:7021-7027.
65. Chase M.A., Wheeler D.S., Lierl K.M., Hughes V.S., Wong H.R., Page K. Hsp72 induces inflammation and regulates cytokine production in Airway Epithelium through a TLR4- and NF- b-dependent mechanism. J.Immunol. 2007, 179:6318-6324.
66. Yang Y., Liu B., Dai J., Srivastava P.K., Zammit D.J., Lefrançois L., Li Z. Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages. Immunity 2007, 26:215-226.
67. Fang H., Wu Y., Huang X., Wang W., Ang B., Cao X., Wan T. Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response. J.Biol. Chem. 2011, 286:30393-30400.
68. Yu M., Wang H., Ding A., Golenbock D.T., Latz E., Czura C.J., Fenton M.J., Tracey K.J., Yang H. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26:174-179.
69. Hreggvidsdottir H.S., Ostberg T., Wähämaa H., Schierbeck H., Aveberger A.C., Klevenvall L., Palmblad K., Ottosson L., Andersson U., Harris H.E. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J.Leukoc. Biol. 2009, 86:655-662.
70. Peter K., Bobik A. HMGB1 signals danger in acute coronary syndrome: emergence of a new risk marker for cardiovascular death?. Atherosclerosis 2012, 221:317-318.
71. Holvoet P., Davey P.C., De Keyzer D., Doukouré M., Deridder E., Bochaton-Piallat M.L., Gabbiani G., Beaufort E., Bishay K., Andrieux N., Benhabilès N., Marguerie G. Oxidized low-density lipoprotein correlates positively with toll-like receptor 2 and interferon regulatory factor-1 and inversely with superoxide dismutase-1 expression: studies in hypercholesterolemic swine and THP-1 cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1558-1565.
72. Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A., Lacy-Hulbert A., El Khoury J., Golenbock D.T., Moore K.J. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 2010, 11:155-161.
73. Falck-Hansen M., Kassiteridi C., Monaco C. Toll-like receptors in atherosclerosis. Int. J. Mol. Sci. 2013, 14:14008-14023.
74. Tsan M.F., Gao B. Endogenous ligands of Toll-like receptors. J.Leukoc. Biol. 2004, 76:514-519.
75. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
76. Lee C.C., Avalos A.M., Ploegh H.L. Accessory molecules for toll-like receptors and their function. Nat. Rev. Immunol. 2012, 12:168-179.
77. Estruch M., Bancells C., Beloki L., Sanchez-Quesada J.L., Ordóñez-Llanos J., Benitez S. CD14 and TLR4 mediate cytokine release promoted by electronegative LDL in monocytes. Atherosclerosis 2013, 229:356-362.
78. Latz E., Xiao T.S., Stutz A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013, 13:397-411.
79. Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G., Abela G.S., Franchi L., Nuñez G., Schnurr M., Espevik T., Lien E., Fitzgerald K.A., Rock K.L., Moore K.J., Wright S.D., Hornung V., Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
80. Rajamäki K., Lappalainen J., Oörni K., Välimäki E., Matikainen S., Kovanen P.T., Eklund K.K. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010, 5:e11765.
81. Sheedy F.J., Grebe A., Rayner K.J., Kalantari P., Ramkhelawon B., Carpenter S.B., Becker C.E., Ediriweera H.N., Mullick A.E., Golenbock D.T., Stuart L.M., Latz E., Fitzgerald K.A., Moore K.J. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol. 2013, 14:812-820.
82. Ridker P.M., Howard C.P., Walter V., Everett B., Libby P., Hensen J., Thuren T. Effects of Interleukin-1β inhibition with canakinumab on Hemoglobin A1c, lipids, c-reactive protein, Interleukin-6, and Fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012, 126:2739-2748. on behalf of the CANTOS Pilot Investigative Group.
83. Freigang S., Ampenberger F., Weiss A., Kanneganti T.D., Iwakura Y., Hersberger M., Kopf M. Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1α and sterile vascular inflammation in atherosclerosis. Nat. Immunol. 2013, 14:1045-1053.
84. Wang M., Krauss J.L., Domon H., Hosur K.B., Liang S., Magotti P., Triantafilou M., Triantafilou K., Lambris J.D., Hajishengallis G. Microbial hijacking of complement-toll-like receptor crosstalk. Sci. Signal 2010, 3:ra11.
85. Hajishengallis G., Lambris J.D. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol. 2010, 31:154-163.
86. Song W.C. Crosstalk between complement and toll-like receptors. Toxicol. Pathol. 2012, 40:174-182.
87. Barratt-Due A., Pischke S.E., Brekke O.L., Thorgersen E.B., Nielsen E.W., Espevik T., Huber-Lang M., Mollnes T.E. Bride and groom in systemic inflammation-the bells ring for complement and Toll in cooperation. Immunobiology 2012, 217:1047-1056.
88. DiMartino S.J., Yuan W., Redecha P., Ivashkiv L.B., Salmon J.E. Insoluble immune complexes are most effective at triggering IL-10 production in human monocytes and synergize with TLR ligands and C5a. Clin. Immunol. 2008, 127:56-65.
89. Okazaki N., Hazeki K., Izumi T., Nigorikawa K., Hazeki O. C5a controls TLR-induced IL-10 and IL-12 production independent of phosphoinositide 3-kinase. J.Biochem. 2011, 149:265-274.
90. Raby A.C., Holst B., Davies J., Colmont C., Laumonnier Y., Coles B., Shah S., Hall J., Topley N., Köhl J., Morgan B.P., Labéta M.O. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. Eur. J. Immunol. 2011, 41:2741-2752.
91. Lau C., Nygård S., Fure H., Olstad O.K., Holden M., Lappegård K.T., Brekke O.L., Espevik T., Hovig E., Mollnes T.E. CD14 and complement crosstalk and Largely mediate the Transcriptional response to Escherichia coli in human whole blood as revealed by DNA microarray. PLoS One 2015, 10:e0117261.
92. Zhang X., Kimura Y., Fang C., Zhou L., Sfyroera G., Lambris J.D., Wetsel R.A., Miwa T., Song W.C. Regulation of Toll-like receptor-mediated inflammatory response by complement invivo. Blood 2007, 110:228-236.
93. Zou L., Feng Y., Li Y., Zhang M., Chen C., Cai J., Gong Y., Wang L., Thurman J.M., Wu X., Atkinson J.P., Chao W. Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis. J.Immunol. 2013, 191:5625-5635.
94. Han C., Jin J., Xu S., Liu H., Li N., Cao X. Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat. Immunol. 2010, 11:734-742.
95. Means T.K., Luster A.D. Integrins limit the Toll. Nat. Immunol. 2010, 11:691-693.
96. Holst B., Raby A.C., Hall J.E., Labéta M.O. Complement takes its Toll: an inflammatory crosstalk between Toll-like receptors and the receptors for the complement anaphylatoxin C5a. Anaesthesia 2012, 67:60-64.
97. Triantafilou K., Hughes T.R., Triantafilou M., Morgan B.P. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J.Cell. Sci. 2013, 126:2903-2913.
98. Asgari E., Le Friec G., Yamamoto H., Perucha E., Sacks S.S., Köhl J., Cook H.T., Kemper C. C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood 2013, 122:3473-3481.
99. Samstad E.O., Niyonzima N., Nymo S., Aune M.H., Ryan L., Bakke S.S., Lappegård K.T., Brekke O.L., Lambris J.D., Damås J.K., Latz E., Mollnes T.E., Espevik T. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J.Immunol. 2014, 192:2837-2845.
100. Markiewski M.M., Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. Complement and coagulation: strangers or partners in crime?. Trends Immunol. 2007, 28:184-192.
101. Amara U., Flierl M.A., Rittirsch D., Klos A., Chen H., Acker B., Brückner U.B., Nilsson B., Gebhard F., Lambris J.D., Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J.Immunol. 2010, 185:5628-5636.
102. Verschoor A., Langer H.F. Crosstalk between platelets and the complement system in immune protection and disease. Thromb. Haemost. 2013, 110:910-919.
103. Owens A.P., Passam F.H., Antoniak S., Marshall S.M., McDaniel A.L., Rudel L., Williams J.C., Hubbard B.K., Dutton J.A., Wang J., Tobias P.S., Curtiss L.K., Daugherty A., Kirchhofer D., Luyendyk J.P., Moriarty P.M., Nagarajan S., Furie B.C., Furie B., Johns D.G., Temel R.E., Mackman N. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J.Clin. Invest 2012, 122:558-568.
104. Barbu A., Hamad O.A., Lind L., Ekdahl K.N., Nilsson B. The role of complement factor C3 in lipid metabolism. Mol. Immunol. 2015, 67(1):101-107.
105. Hajishengallis G., Lambris J.D. Microbial manipulation of receptor crosstalk in innate immunity. Nat. Rev. Immunol. 2011, 11:187-200.
106. Reddick L.E., Alto N.M. Bacteria fighting back: how pathogens target and subvert the host innate immune system. Mol. Cell. 2014, 54:321-328.
107. Brekke O.L., Christiansen D., Fure H., Fung M., Mollnes T.E. The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J.Leukoc. Biol. 2007, 81:1404-1413.
108. Brekke O.L., Christiansen D., Fure H., Pharo A., Fung M., Riesenfeld J., Mollnes T.E. Combined inhibition of complement and CD14 abolish E. coli-induced cytokine-, chemokine- and growth factor-synthesis in human whole blood. Mol. Immunol. 2008, 45:3804-3813.
109. Salvesen B., Fung M., Saugstad O.D., Mollnes T.E. Role of complement and CD14 in meconium-induced cytokine formation. Pediatrics 2008, 121:e496-e505.
110. Barratt-Due A., Thorgersen E.B., Egge K., Pischke S., Sokolov A., Hellerud B.C., Lindstad J.K., Pharo A., Bongoni A.K., Rieben R., Nunn M., Scott H., Mollnes T.E. Combined inhibition of complement (C5) and CD14 markedly attenuates inflammation, Thrombogenicity, and hemodynamic changes in porcine sepsis. J.Immunol. 2013, 191:819-827.
111. Jennings R.B. Historical perspective on the pathology of myocardial ischemia/reperfusion injury. Circ. Res. 2013, 113:428-438.
112. Zhao H., Perez J.S., Lu K., George A.J., Ma D. Role of toll-like receptor-4 in renal graft ischemia-reperfusion injury. Am. J. Physiol. Ren. Physiol. 2014, 306:F801-F811.
113. Damman J., Daha M.R., van Son W.J., Leuvenink H.G., Ploeg R.J., Seelen M.A. Crosstalk between complement and toll-like receptor activation in relation to donor brain death and renal ischemia-reperfusion injury. Am. J. Transpl. 2011, 11:660-669.
114. Saba R., Sorensen D.L., Booth S.A. MicroRNA-146a: a dominant, negative regulator of the innate immune response. Front. Immunol. 2014, 5:578.
115. Pareek S., Roy S., Kumari B., Jain P., Banerjee A., Vrati S. MiR-155 induction in microglial cells suppresses Japanese encephalitis virus replication and negatively modulates innate immune responses. J.Neuroinflammation 2014, 11:97.
116. Eadon M.T., Jacob A., Cunningham P.N., Quigg R.J., Garcia J.G., Alexander J.J. Transcriptional profiling reveals that C5a alters microRNA in brain endothelial cells. Immunology 2014, 143:363-373.
117. Norata G.D., Sala F., Catapano A.L., Fernández-Hernando C. MicroRNAs and lipoproteins: a connection beyond atherosclerosis?. Atherosclerosis 2013, 227:209-215.
118. Francescut L., Steiner T., Byrne S., Cianflone K., Francis S., Stover C. The role of complement in the development and manifestation of murine atherogenic inflammation: novel avenues. J.Innate Immun. 2012, 4:260-272.
119. Wu G., Hu W., Shahsafaei A., Song W., Dobarro M., Sukhova G.K., Bronson R.R., Shi G.P., Rother R.P., Halperin J.A., Qin X. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ. Res. 2009, 104:550-558.
120. Schmiedt W., Kinscherf R., Deigner -P., Kamencic H., Nauen O., Kilo J., Oelert H., Metz J., Bhakdi S. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1790-1795.
121. Patel S., Thelander E.M., Hernandez M., Montenegro J., Hassing H., Burton C., Mundt S., Hermanowski-Vosatka A., Wright S.D., Chao Y.S., Detmers P.A. ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. Biochem. Biophys. Res. Commun. 2001, 286:164-170.
122. Hasselbacher P., Hahn J. Invitro effects of radiographic contrast media on the complement system. J.Allergy Clin. Immunol. 1980, 66:217-222.
123. Nymo S., Niyonzima N., Espevik T., Mollnes T.E. Cholesterol crystal-induced endothelial cell activation is complement-dependent and mediated by TNF. Immunobiology 2014, 219:786-792.
124. Subramanian M., Thorp E., Hansson G.K., Tabas I. Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J.Clin. Invest 2013, 123:179-188.
125. Yu M., Zhou H., Zhao J., Xiao N., Roychowdhury S., Schmitt D., Hu B., Harding C.V., Hise A.G., Hazen S.L., Defranco A.L., Fox P.L., Morton R.E., Dicorleto P.E., Febbraio M., Nagy L.E., Smith J.D., Wang J.A., Li X. MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases. J.Exp. Med. 2014, 211:887-907.
126. Warren H.S., Tompkins R.G., Moldawer L.L., Seok J., Xu W., Mindrinos M.N., Maier R.V., Xiao W., Davis R.W. Mice are not men. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:E345.
127. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
128. Bhakdi S., Torzewski M., Klouche M., Hemmes M. Complement and atherogenesis : binding of CRP to Degraded, Nonoxidized LDL enhances complement activation. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2348-2354.
129. Bhakdi S., Torzewski M., Paprotka K., Schmitt S., Barsoom H., Suriyaphol P., Han S.R., Lackner K.J., Husmann M. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 2004, 109:1870-1876.
130. Fraser D.A., Tenner A.J. Innate immune proteins C1q and mannan-binding lectin enhance clearance of atherogenic lipoproteins by human monocytes and macrophages. J.Immunol. 2010, 185:3932-3939.
131. Chávez-Sánchez L., Madrid-Miller A., Chávez-Rueda K., Legorreta-Haquet M.V., Tesoro-Cruz E., Blanco-Favela F. Activation of TLR2 and TLR4 by minimally modified low-density lipoprotein in human macrophages and monocytes triggers the inflammatory response. Hum. Immunol. 2010, 71:737-744.
132. Su X., Ao L., Shi Y., Johnson T.R., Fullerton D.A., Meng X. Oxidized low density lipoprotein induces bone morphogenetic protein-2 in coronary artery endothelial cells via Toll-like receptors 2 and 4. J.Biol. Chem. 2011, 286:12213-12220.
133. Smolinska M.J., Page T.H., Urbaniak A.M., Mutch B.E., Horwood N.J. Hck tyrosine kinase regulates TLR4-induced TNF and IL-6 production via AP-1. J.Immunol. 2011, 187:6043-6051.
134. Mogilenko D.A., Kudriavtsev I.V., Trulioff A.S., Shavva V.S., Dizhe E.B., Missyul B.V., Zhakhov A.V., Ischenko A.M., Perevozchikov A.P., Orlov S.V. Modified low density lipoprotein stimulates complement C3 expression and secretion via liver X receptor and Toll-like receptor 4 activation in human macrophages. J.Biol. Chem. 2012, 287:5954-5968.
135. Oksjoki R., Laine P., Helske S., Vehmaan-Kreula P., Mäyränpää M.I., Gasque P., Kovanen P.T., Pentikäinen M.O. Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques. Atherosclerosis 2007, 195:90-99.
136. Vijayan S., Asare Y., Grommes J., Soehnlein O., Lutgens E., Shagdarsuren G., Togtokh A., Jacobs M., Fischer J.W., Bernhagen J., Weber C., Schober A., Shagdarsuren E. High expression of C5L2 correlates with high proinflammatory cytokine expression in advanced human atherosclerotic plaques. Am. J. Pathol. 2014, 184:2123-2133.
137. Helske S., Oksjoki R., Lindstedt K.A., Lommi J., Turto H., Werkkala K., Kupari M., Kovanen P.T. Complement system is activated in stenotic aortic valves. Atherosclerosis 2008, 196:190-200.
138. ter Weeme M., Vonk A.B., Kupreishvili K., van Ham M., Zeerleder S., Wouters D., Stooker W., Eijsman L., Van Hinsbergh V.W., Krijnen P.A., Niessen H.W. Activated complement is more extensively present in diseased aortic valves than naturally occurring complement inhibitors: a sign of ongoing inflammation. Eur. J. Clin. Invest 2010, 40:4-10.
139. Xu H., Shah K., Faure E., Equils O., Thomas L., Fishbein C., Luthringer D., Xu -P., Rajavashisth B., Yano J., Kaul S., Arditi M. Toll-like Receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001, 104:3103-3108.
140. Edfeldt K., Swedenborg J., Hansson G.K., Yan Z.Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002, 105:1158-1161.
141. Malgor R., Bhatt P.M., Connolly B.A., Jacoby D.L., Feldmann K.J., Silver M.J., Nakazawa M., McCall K.D., Goetz D.J. Wnt5a, TLR2 and TLR4 are elevated in advanced human atherosclerotic lesions. Inflamm. Res. 2014, 63:277-285.
142. Mullick A.E., Soldau K., Kiosses W.B., Bell T.A., Tobias P.S., Curtiss L.K. Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J.Exp. Med. 2008, 205:373-383.
143. Libby P., Lichtman A.H., Hansson G.K. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 2013, 38:1092-1104.
144. Capuano V., D'Arminio T., La Sala G., Mazzotta G. The third component of the complement (C3) is a marker of the risk of atherogenesis. Eur. J. Cardiovasc Prev. Rehabil. 2006, 13:658-660.
145. Engström G., Hedblad B., Janzon L., Lindgärde F. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur. J. Cardiovasc Prev. Rehabil. 2007, 14:392-397.
146. van Greevenbroek M.M., Jacobs M., van der Kallen C.J., Vermeulen V.M., Jansen E.H., Schalkwijk C.G., Ferreira I., Feskens E.J., Stehouwer C.D. The cross-sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM study). Eur. J. Clin. Invest 2011, 41:372-379.
147. Wlazlo N., van Greevenbroek M.M., Ferreira I., Jansen E.J., Feskens E.J., van der Kallen C.J., Schalkwijk C.G., Bravenboer B., Stehouwer C.D. Low-grade inflammation and insulin resistance independently explain substantial parts of the association between body fat and serum C3: the CODAM study. Metabolism 2012, 61:1787-1796.
148. Nilsson B., Hamad O.A., Ahlström H., Kullberg J., Johansson L., Lindhagen L., Haenni A., Ekdahl K.N., Lind L. C3 and C4 are strongly related to Adipose tissue variables and cardiovascular risk factors. Eur. J. Clin. Invest 2014, 44:587-596.
149. Palikhe A., Sinisalo J., Seppänen M., Haario H., Meri S., Valtonen V., Nieminen M.S., Lokki M.L. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am. J. Cardiol. 2007, 99:890-895.
150. Hertle E., van Greevenbroek M., Arts I.C., van der Kallen C.J., Geijselaers S.L., Feskens E.J., Jansen E.H., Schalkwijk C.G., Stehouwer C.D. Distinct associations of complement C3a and its precursor C3 with atherosclerosis and cardiovascular disease. The CODAM study. Thromb. Haemost. 2014, 111:1102-1111.
151. Patzelt J., Mueller K.A., Breuning S., Karathanos A., Schleicher R., Seizer P., Gawaz M., Langer H.F., Geisler T. Expression of anaphylatoxin receptors on platelets in patients with coronary heart disease. Atherosclerosis 2015, 238:289-295.
152. Selejan S., Pöss J., Walter F., Hohl M., Kaiser R., Kazakov A., Böhm M., Link A. Ischaemia-induced up-regulation of Toll-like receptor 2 in circulating monocytes in cardiogenic shock. Eur. Heart J. 2012, 33:1085-1094.
153. Yonekawa K., Neidhart M., Altwegg L.A., Wyss C.A., Corti R., Vogl T., Grigorian M., Gay S., Lüscher T.F., Maier W. Myeloid related proteins activate Toll-like receptor 4 in human acute coronary syndromes. Atherosclerosis 2011, 218:486-492.
154. Satoh M., Shimoda Y., Maesawa C., Akatsu T., Ishikawa Y., Minami Y., Hiramori K., Nakamura M. Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int. J. Cardiol. 2006, 109:226-234.
155. Kashiwagi M., Imanishi T., Ozaki Y., Satogami K., Masuno T., Wada T., Nakatani Y., Ishibashi K., Komukai K., Tanimoto T., Ino Y., Kitabata H., Akasaka T. Differential expression of Toll-like receptor 4 and human monocyte subsets in acute myocardial infarction. Atherosclerosis 2012, 221:249-253.
156. Versteeg D., Hoefer I.E., Schoneveld A.H., de Kleijn D.P., Busser E., Strijder C., Emons M., Stella P.R., Doevendans P.A., Pasterkamp G. Monocyte toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve. Heart 2008, 94:770-776.
157. Elsenberg E.H., Sels J.E., Hillaert M.A., Schoneveld A.H., van den Dungen N.A., van Holten T.C., Roest M., Jukema J.W., van Zonneveld A.J., de Groot P.G., Pijls N., Pasterkamp G., Hoefer I.E. Increased cytokine response after toll-like receptor stimulation in patients with stable coronary artery disease. Atherosclerosis 2013, 231:346-351.
158. Blaskó B., Kolka R., Thorbjornsdottir P., Sigurdarson S.T., Sigurdsson G., Rónai Z., Sasvári-Székely M., Bödvarsson S., Thorgeirsson G., Prohászka Z., Kovács M., Füst G., Arason G.J. Low complement C4B gene copy number predicts short-term mortality after acute myocardial infarction. Int. Immunol. 2008, 20:31-37.
159. Symmons D.P., Gabriel S.E. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat. Rev. Rheumatol. 2011, 7:399-408.
160. Troelsen L.N., Garred P., Christiansen B., Torp-Pedersen C., Christensen I.J., Narvestad E., Jacobsen S. Double role of mannose-binding lectin in relation to carotid intima-media thickness in patients with rheumatoid arthritis. Mol. Immunol. 2010, 47:713-718.
161. Alipour A., Cabezas M.C., Elte J.W., Vallvé J.C., Ribalta J., Zwinderman A.H., Defesche J.C., Jukema J.W. Mannose binding lectin 2 haplotypes do not affect the progression of coronary atherosclerosis in men with proven coronary artery disease treated with pravastatin. Atherosclerosis 2011, 215:125-129.
162. Siezenga M.A., Shaw P.K., Daha M.R., Rabelink T.J., Berger S.P. Low Mannose-Binding Lectin (MBL) genotype is associated with future cardiovascular events in type 2 diabetic South Asians. A prospective cohort study. Cardiovasc Diabetol. 2011, 10:60.
163. Vengen I.T., Madsen H.O., Garred P., Platou C., Vatten L., Videm V. Mannose-binding lectin deficiency is associated with myocardial infarction: the HUNT2 study in Norway. PLoS One 2012, 7:e42113.
164. Øhlenschlaeger T., Garred P., Madsen H.O., Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N.Engl. J. Med. 2004, 351:260-267.
165. Mellbin L.G., Bjerre M., Thiel S., Hansen T.K. Complement activation and prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care 2012, 35:911-917.
166. Frauenknecht V., Thiel S., Storm L., Meier N., Arnold M., Schmid J.P., Saner H., Schroeder V. Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases. Clin. Exp. Immunol. 2013, 173:112-120.
167. Hoke M., Speidl W., Schillinger M., Minar E., Zehetmayer S., Schönherr M., Wagner O., Mannhalter C. Polymorphism of the complement 5 gene and cardiovascular outcome in patients with atherosclerosis. Eur. J. Clin. Invest 2012, 42:921-926.
168. Parra S., Vives G., Ferré R., González M., Guardiola M., Ribalta J., Castro A. Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients. Atherosclerosis 2012, 225:224-230.
169. Sofat R., Casas J.P., Kumari M., Talmud P.J., Ireland H., Kivimaki M., Marmot M., Hughes A.D., Thom S., Ebrahim S., Whittaker J.C., Smeeth L., Lawlor D.A., Humphries S.E., Hingorani A.D. Genetic variation in complement factor H and risk of coronary heart disease: eight new studies and a meta-analysis of around 48,000 individuals. Atherosclerosis 2010, 213:184-190.
170. Koeijvoets K.C., Mooijaart S.P., Dallinga-Thie G.M., Defesche J.C., Steyerberg E.W., Westendorp R.G., Kastelein J.J., van Hagen P.M., Sijbrands E.J. Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia. Eur. Heart J. 2009, 30:618-623.
171. Labrum R., Bevan S., Sitzer M., Lorenz M., Markus H.S. Toll receptor polymorphisms and carotid artery intima-media thickness. Stroke 2007, 38:1179-1184.
172. Ferronato S., Gomez-Lira M., Menegazzi M., Diani E., Olivato S., Sartori M., Scuro A., Malerba G., Pignatti P.F., Romanelli M.G., Mazzucco S. Polymorphism -2604G>A variants in TLR4 promoter are associated with different gene expression level in peripheral blood of atherosclerotic patients. J.Hum. Genet. 2013, 58:812-814.
173. Enquobahrie D.A., Smith N.L., Bis J.C., Carty C.L., Rice K.M., Lumley T., Hindorff L.A., Lemaitre R.N., Williams M.A., Siscovick D.S., Heckbert S.R., Psaty B.M. Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, and Toll-like receptor 4 genetic variations and risk of incident nonfatal myocardial infarction and ischemic stroke. Am. J. Cardiol. 2008, 101:1683-1688.
174. Džumhur A., Zibar L., Wagner J., Simundić T., Dembić Z., Barbić J. Association studies of gene polymorphisms in toll-like receptors 2 and 4 in croatian patients with acute myocardial infarction. Scand. J. Immunol. 2012, 75:517-523.
175. Lu X., Xia M., Endresz V., Faludi I., Mundkur L., Gonczol E., Chen D., Kakkar V.V. Immunization with a combination of 2 peptides derived from the C5a receptor significantly reduces early atherosclerotic lesion in Ldlrtm1Her Apobtm2SgyJ mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2358-2371.
176. Shagdarsuren E., Bidzhekov K., Mause S.F., Simsekyilmaz S., Polakowski T., Hawlisch H., Gessner J.E., Zernecke A., Weber C. C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice. Circulation 2010, 122:1026-1036.
177. Shernan S.K., Fitch J.C., Nussmeier N.A., Chen J.C., Rollins S.A., Mojcik C.F., Malloy K.J., Todaro T.G., Filloon T., Boyce S.W., Gangahar D.M., Goldberg M., Saidman L.J., Mangano D.T. Pexelizumab study Investigators. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann. Thorac. Surg. 2004, 77:942-949. discussion 949-50.
178. Verrier E.D., Shernan S.K., Taylor K.M., Van de Werf F., Newman M.F., Chen J.C., Carrier M., Haverich A., Malloy K.J., Adams P.X., Todaro T.G., Mojcik C.F., Rollins S.A., Levy J.H. PRIMO-CABG Investigators. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA 2004, 291:2319-2327.
179. Armstrong P.W., Granger C.B., Adams P.X., Hamm C., Holmes D., O'Neill W.W., Todaro T.G., Vahanian A., Van de Werf F. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007, 297:43-51.
180. Mahaffey K.W., Van de Werf F., Shernan S.K., Granger C.B., Verrier E.D., Filloon T.G., Todaro T.G., Adams P.X., Levy J.H., Hasselblad V., Armstrong P.W. Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. Am. Heart J. 2006, 152:291-296.
181. Martel C., Granger C.B., Ghitescu M., Stebbins A., Fortier A., Armstrong P.W., Bonnefoy A., Theroux P. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Am. Heart J. 2012, 164:43-51.
182. Mendel I., Feige E., Yacov N., Salem Y., Levi I., Propheta-Meiran O., Shoham A., Ishai E., George J., Harats D., Breitbart E. VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis. Clin. Exp. Immunol. 2014, 175:126-137.
183. Chen G.Y., Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 2010, 10:826-837.
184. Mollnes T.E., Christiansen D., Brekke E.O.L., Espevik T. Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. Adv. Exp. Med. Biol. 2008, 632:253-263.
185. Bhatia V.K., Yun S., Leung V., Grimsditch D.C., Benson G.M., Botto M.B., Boyle J.J., Haskard D.O. Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am. J. Pathol. 2007, 170:416-426.
186. Lewis M.J., Malik T.H., Ehrenstein M.R., Boyle J.J., Botto M., Haskard D.O. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009, 120:417-426.
187. Matthijsen R.A., de Winther M.P., Kuipers D., van der Made I., Weber C., Herias M.V., Gijbels M.J., Buurman W.A. Macrophage-specific expression of mannose-binding lectin controls atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009, 119:2188-2195.
188. Orsini F., Villa P., Parrella S., Zangari R., Zanier E.R., Gesuete R., Stravalaci M., Fumagalli S., Ottria R., Reina J.J., Paladini A., Micotti E., Ribeiro-Viana R., Rojo J., Pavlov V.I., Stahl G.L., Bernardi A., Gobbi M., De Simoni M.G. Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation 2012, 126:1484-1494.
189. Malik T.H., Cortini A., Carassiti D., Boyle J.J., Haskard D.O., Botto M. The alternative pathway is critical for pathogenic complement activation in endotoxin- and diet-induced atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2010, 122:1948-1956.
190. Manthey H.D., Thomas A.C., Shiels I.A., Zernecke A., Woodruff T.M., Rolfe B., Taylor S.M. Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice. FASEB J. 2011, 25:2447-2455.
191. Sakuma M., Morooka T., Wang Y., Shi C., Croce K., Gao H., Strainic M., Medof M.E., Simon D.I. The Intrinsic complement regulator decay-accelerating factor modulates the biological response to vascular injury. Arterioscler. Thromb. Vasc. Biol. 2010, 30. 1196-202.
192. Lewis R.D., Perry M.J., Guschina I.A., Jackson C.L., Morgan B.P., Hughes T.R. CD55 deficiency protects against atherosclerosis in ApoE-deficient mice via C3a modulation of lipid metabolism. Am. J. Pathol. 2011, 179:1601-1607.
193. Liu F., Wu L., Wu G., Wang C., Zhang L., Tomlinson S., Qin X. Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice. Atherosclerosis 2014, 234:237-243.
194. Yvan-Charvet L., Welch C., Pagler T.A., Ranalletta M., Lamkanfi M., Han S., Ishibashi M., Li R., Wang N., Tall A.R. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation 2008, 118:1837-1847.
195. Liu N., Liu J., Ji Y., Lu P. Toll-like receptor 4 signaling mediates inflammatory activation induced by C-reactive protein in vascular smooth muscle cells. Cell. Physiology Biochem. 2010, 25:467-476.
196. Ding Y., Subramanian S., Montes V.N., Goodspeed L., Wang S., Han C., Teresa A.S., Kim J., O'Brien K.D., Chait A. Toll-like receptor 4 deficiency decreases atherosclerosis but does not protect against inflammation in obese low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1596-1604.
197. Hayashi C., Papadopoulos G., Gudino C.V., Weinberg E.O., Barth K.R., Madrigal A.G., Chen Y., Ning H., LaValley M., Gibson F.C., Hamilton J.A., Genco C.A. Protective role for TLR4 signaling in atherosclerosis progression as revealed by infection with a common oral pathogen. J.Immunol. 2012, 189:3681-3688.
198. Curtiss L.K., Black A.S., Bonnet D.J., Tobias P.S. Atherosclerosis induced by endogenous and exogenous toll-like receptor (TLR)1 or TLR6 agonists. J.Lipid Res. 2012, 53:2126-2132.
199. Karper J.C., Ewing M.M., Habets K.L., de Vries M.R., Peters E.A., van Oeveren-Rietdijk A.M., de Boer H.C., Hamming J.F., Kuiper J., Kandimalla E.R., La Monica N., Jukema J.W., Quax P.H. Blocking toll-like receptors 7 and 9 reduces postinterventional remodeling via reduced macrophage activation, foam cell formation, and migration. Arterioscler. Thromb. Vasc. Biol. 2012, 32:e72-e80.
200. Polykratis A., van Loo G., Xanthoulea S., Hellmich M., Pasparakis M. Conditional targeting of tumor necrosis factor receptor-associated factor 6 reveals opposing functions of toll-like receptor signaling in endothelial and myeloid cells in a mouse model of atherosclerosis. Circulation 2012, 126:1739-1751.
201. Koulis C., Chen Y.C., Hausding C., Ahrens I., Kyaw T.S., Tay C., Allen T., Jandeleit-Dahm K., Sweet M.J., Akira S., Bobik A., Peter K., Agrotis A. Protective role for toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2014, 34:516-525.